Cyclophosphamide

Acute Coryza, Retinoblastoma, histiocytic lymphoma + 20 more
Treatment
21 FDA approvals
20 Active Studies for Cyclophosphamide

What is Cyclophosphamide

CyclophosphamideThe Generic name of this drug
Treatment SummaryCyclophosphamide is a medication used to treat cancer, including lymphoma and leukemia. It must be processed in the liver to become an active form of chemotherapy. Side effects of the drug include hair loss, infertility, birth defects, and an increased risk of cancer. It is also used to shear sheep.
Cyclophosphamideis the brand name
image of different drug pills on a surface
Cyclophosphamide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Cyclophosphamide
Cyclophosphamide
1959
75

Approved as Treatment by the FDA

Cyclophosphamide, otherwise called Cyclophosphamide, is approved by the FDA for 21 uses like Erythema Induratum and Hodgkin Disease .
Erythema Induratum
Hodgkin Disease
Lung Cancer
failure with corticosteroid therapy
chronic Granulocytic Leukemias
Lymphocytic Lymphomas
Adenocarcinoma
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia
mixed-cell type lymphoma
Malignant Lymphomas
Multiple Myeloma
Breast Cancer
Retinoblastoma
Acute Myeloid Leukemia
Leukemia, Myelocytic, Acute
histiocytic lymphoma
Chronic Lymphocytic Leukemia
Acute Coryza
Disseminated Neuroblastoma
Glomerulonephritis

Effectiveness

How Cyclophosphamide Affects PatientsCyclophosphamide is a type of medication used to treat cancer. It works by adding chemicals called alkyl groups to DNA, which prevents the cells from dividing and stops them from growing. It also adds methyl or other alkyl groups to molecules that should not be there, which disrupts how DNA works and causes the cells to die. Alkylating agents are cell cycle-nonspecific, meaning they affect any cell at any stage of its life cycle.
How Cyclophosphamide works in the bodyAlkylating agents are drugs that prevent cancer cells from reproducing by damaging their DNA. They do this in three ways: by attaching alkyl molecules to the DNA, creating bonds between the atoms of the DNA, and causing the nucleotides to mispair. As a result of this damage, the DNA is unable to be copied, preventing further cancer cell growth.

When to interrupt dosage

The advised dosage of Cyclophosphamide is contingent upon the diagnosed condition, for example Lymphoma, Glomerulonephritis and Leukemia, Myelocytic, Acute. The measure of dosage varies depending on the administration technique (e.g. Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular or Powder, for solution - Intravenous) featured in the table below.
Condition
Dosage
Administration
Erythema Induratum
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Non-Hodgkin's Lymphoma
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Multiple Myeloma
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
failure with corticosteroid therapy
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Disseminated Neuroblastoma
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Adenocarcinoma
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lymphocytic Lymphomas
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Hodgkin Disease
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
histiocytic lymphoma
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Breast Cancer
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Multiple Sclerosis
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Malignant Lymphomas
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Leukemia, Myelocytic, Acute
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Retinoblastoma
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
mixed-cell type lymphoma
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Glomerulonephritis
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Acute Lymphoblastic Leukemia
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
chronic Granulocytic Leukemias
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lung Cancer
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lupus
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Warnings

Cyclophosphamide Contraindications
Condition
Risk Level
Notes
severely depressed bone marrow function
Do Not Combine
Bladder Outlet Obstruction
Do Not Combine
There are 20 known major drug interactions with Cyclophosphamide.
Common Cyclophosphamide Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Cyclophosphamide.
Abetimus
Major
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Abetimus.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Cyclophosphamide.
Cyclophosphamide Toxicity & Overdose RiskCommon side effects of taking this drug include lowered white blood cell count, fever, hair loss, nausea, vomiting, and diarrhea.
image of a doctor in a lab doing drug, clinical research

Cyclophosphamide Novel Uses: Which Conditions Have a Clinical Trial Featuring Cyclophosphamide?

1165 active clinical trials are currently being conducted to examine the potential of Cyclophosphamide to treat Breast Cancer, Lymphocytic Lymphomas and Multiple Myeloma.
Condition
Clinical Trials
Trial Phases
Lupus
2 Actively Recruiting
Not Applicable, Phase 1
mixed-cell type lymphoma
0 Actively Recruiting
Acute Myeloid Leukemia
315 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1, Phase 4
Erythema Induratum
0 Actively Recruiting
Lymphocytic Lymphomas
0 Actively Recruiting
Adenocarcinoma
3 Actively Recruiting
Phase 2, Phase 1
Disseminated Neuroblastoma
0 Actively Recruiting
histiocytic lymphoma
0 Actively Recruiting
Acute Coryza
0 Actively Recruiting
Malignant Lymphomas
3 Actively Recruiting
Phase 1
Glomerulonephritis
0 Actively Recruiting
Hodgkin Disease
4 Actively Recruiting
Not Applicable, Phase 1
chronic Granulocytic Leukemias
0 Actively Recruiting
Leukemia, Myelocytic, Acute
0 Actively Recruiting
failure with corticosteroid therapy
0 Actively Recruiting
Acute Lymphoblastic Leukemia
146 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable, Early Phase 1, Phase 4
Multiple Sclerosis
195 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 1, Phase 4, Early Phase 1
Retinoblastoma
12 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1
Multiple Myeloma
12 Actively Recruiting
Phase 2, Phase 1
Breast Cancer
713 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4

Cyclophosphamide Reviews: What are patients saying about Cyclophosphamide?

5Patient Review
9/13/2010
Cyclophosphamide for Scleroderma Lung Disease
I've been on this medication for a short time, so it's hard to say if it's effective yet. I have noticed some hair loss and decreased appetite. When I do eat, I sometimes feel nauseous. It seems like my breathing is better, but the change has been very gradual.
4.7Patient Review
3/15/2011
Cyclophosphamide for Cancer of the Ovary
This medicine has been incredibly effective, moreso than I could have hoped. My doctors decided to try something new on my 8th battle with cancer, and I'm so glad they did. As a college student, it's important to me that I can still go to school and work while taking this medication. The nausea has been tough to deal with but it's better than chemotherapy by far.
4.7Patient Review
5/26/2008
Cyclophosphamide for Breast Cancer that has Spread to Another Part of the Body
4.3Patient Review
9/1/2012
Cyclophosphamide for Scleroderma Lung Disease
I took this medication to get my Lupus under control, and it was successful. However, I experienced some troubling side effects afterwards that required me to take another medication. Thankfully, my liver returned to normal a few months later.
4Patient Review
8/1/2008
Cyclophosphamide for Multiple Myeloma
3.7Patient Review
10/13/2010
Cyclophosphamide for Malignant Tumor of the Kidney
I've been on this drug for over two years now and have had no significant side effects. My PFTs (not sure what this stands for) were stable when I switched to this medication, and I take 5mg of prednisone daily as well.
3.3Patient Review
5/12/2009
Cyclophosphamide for Nephrotic Syndrome
I experienced few side effects with this drug, which is great compared to many other drugs I've tried. The only downside is that it didn't completely solve my hair loss issue, but it did help somewhat.
3Patient Review
2/4/2014
Cyclophosphamide for Acute Monocytic Leukemia
I experienced a lot of abdominal pain, pelvic pain, cramps, burning, and watery stools while on this medication. I also had anal pressure and pain, gas, bloating, and a frequent urge to defecate. As a result of all these side effects, I lost weight and my appetite completely vanished. I have been off the medication for almost two months now and I still haven't had a normal stool.
3Patient Review
7/23/2009
Cyclophosphamide for Scleroderma Lung Disease
My father had to be taken off this drug due to mental side effects. He was also taking dexamethasone, which may have contributed to the confusion and delusions he experienced.
2.7Patient Review
10/26/2007
Cyclophosphamide for Breast Cancer that has Spread to Another Part of the Body
2.7Patient Review
2/18/2009
Cyclophosphamide for Cancer of the Ovary
2Patient Review
4/30/2012
Cyclophosphamide for Systemic Lupus Erythematosus
I started this medication after my OC recurred. So far, I'm liking it because I haven't experienced any hair loss or severe nausea.
1Patient Review
1/14/2013
Cyclophosphamide for Cancer of the Ovary
I have now been on Cellcept twice, and can attest to its ineffectiveness. Not only does it lower your immunity to the point where you become susceptible to infection, but it also doesn't do anything to prevent the Scleroderma from coming back.
1Patient Review
3/15/2009
Cyclophosphamide for Acute Monocytic Leukemia
I have recently been placed on this medication, but I haven't taken it for long enough to know if it's effective.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cyclophosphamide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is cyclophosphamide a chemo or immunotherapy?

"Cyclophosphamide is an alkylating chemotherapeutic agent that suppresses the immune system."

Answered by AI

What is the cyclophosphamide used for?

"Cyclophosphamide is a medication used to treat cancer in various parts of the body, including the ovaries, breast, blood and lymph system, nerves, and eyes. It is also used for treating multiple myeloma and skin tumors."

Answered by AI

Is cyclophosphamide a steroid?

"Cyclophosphamide is sometimes called a "steroid-sparing agent" because it has different side effects than prednisone."

Answered by AI

How cyclophosphamide is given?

"This medication can be administered in various ways depending on the diagnosis, including intravenously, orally in tablet form, or by injection into a muscle, the abdominal lining, or the lining of the lung."

Answered by AI

Clinical Trials for Cyclophosphamide

Have you considered Cyclophosphamide clinical trials? We made a collection of clinical trials featuring Cyclophosphamide, we think they might fit your search criteria.
Have you considered Cyclophosphamide clinical trials? We made a collection of clinical trials featuring Cyclophosphamide, we think they might fit your search criteria.
Have you considered Cyclophosphamide clinical trials? We made a collection of clinical trials featuring Cyclophosphamide, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top